- Home
- IPXX vs TOVX Comparison
IPXX vs TOVX Comparison
Compare IPXX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPXX
- TOVX
- Stock Information
- Founded
- IPXX 2023
- TOVX 2001
- Country
- IPXX United States
- TOVX United States
- Employees
- IPXX N/A
- TOVX N/A
- Industry
- IPXX Blank Checks
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IPXX Finance
- TOVX Health Care
- Exchange
- IPXX Nasdaq
- TOVX Nasdaq
- Market Cap
- IPXX 337.5M
- TOVX 3.5M
- IPO Year
- IPXX 2023
- TOVX 2006
- Fundamental
- Price
- IPXX $10.99
- TOVX $1.14
- Analyst Decision
- IPXX
- TOVX Strong Buy
- Analyst Count
- IPXX 0
- TOVX 1
- Target Price
- IPXX N/A
- TOVX $6.00
- AVG Volume (30 Days)
- IPXX 14.0K
- TOVX 96.3K
- Earning Date
- IPXX 01-01-0001
- TOVX 11-12-2024
- Dividend Yield
- IPXX N/A
- TOVX N/A
- EPS Growth
- IPXX N/A
- TOVX N/A
- EPS
- IPXX 0.37
- TOVX N/A
- Revenue
- IPXX N/A
- TOVX N/A
- Revenue This Year
- IPXX N/A
- TOVX N/A
- Revenue Next Year
- IPXX N/A
- TOVX N/A
- P/E Ratio
- IPXX $29.44
- TOVX N/A
- Revenue Growth
- IPXX N/A
- TOVX N/A
- 52 Week Low
- IPXX $10.31
- TOVX $1.14
- 52 Week High
- IPXX $15.18
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- IPXX 44.61
- TOVX 36.15
- Support Level
- IPXX $10.76
- TOVX $1.23
- Resistance Level
- IPXX $15.18
- TOVX $1.21
- Average True Range (ATR)
- IPXX 0.86
- TOVX 0.07
- MACD
- IPXX -0.16
- TOVX 0.01
- Stochastic Oscillator
- IPXX 5.23
- TOVX 0.00
About IPXX Inflection Point Acquisition Corp. II
Inflection Point Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.